In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
Axsome Therapeutics Inc (NASDAQ: AXSM) closed the day trading at $167.55 down -1.84% from the previous closing price of $170.69. In other words, the price has decreased by -$1.84 from its previous closing price. On the day, 0.75 million shares were traded. AXSM stock price reached its highest trading level at $170.59 during the session, while it also had its lowest trading level at $165.7501.
Ratios:
For a better understanding of AXSM, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.50 and its Current Ratio is at 1.57. In the meantime, Its Debt-to-Equity ratio is 2.96 whereas as Long-Term Debt/Eq ratio is at 1.97.
On October 01, 2025, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $179.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 05 ’26 when TABUTEAU HERRIOT sold 78,703 shares for $171.28 per share. The transaction valued at 13,480,250 led to the insider holds 7,229 shares of the business.
TABUTEAU HERRIOT sold 31,261 shares of AXSM for $5,326,249 on Jan 07 ’26. The Chief Executive Officer now owns 7,229 shares after completing the transaction at $170.38 per share. On Jan 06 ’26, another insider, TABUTEAU HERRIOT, who serves as the Chief Executive Officer of the company, sold 29,450 shares for $172.33 each. As a result, the insider received 5,075,118 and left with 7,229 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AXSM now has a Market Capitalization of 8446638080 and an Enterprise Value of 8339961856. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.05 while its Price-to-Book (P/B) ratio in mrq is 114.33. Its current Enterprise Value per Revenue stands at 14.859 whereas that against EBITDA is -44.374.
Stock Price History:
The Beta on a monthly basis for AXSM is 0.40, which has changed by 1.1322923 over the last 52 weeks, in comparison to a change of 0.1877265 over the same period for the S&P500. Over the past 52 weeks, AXSM has reached a high of $184.40, while it has fallen to a 52-week low of $79.19. The 50-Day Moving Average of the stock is 12.85%, while the 200-Day Moving Average is calculated to be 38.67%.
Shares Statistics:
Over the past 3-months, AXSM traded about 590.78K shares per day on average, while over the past 10 days, AXSM traded about 929650 shares per day. A total of 50.31M shares are outstanding, with a floating share count of 41.48M. Insiders hold about 17.73% of the company’s shares, while institutions hold 73.87% stake in the company. Shares short for AXSM as of 1765756800 were 2835683 with a Short Ratio of 4.80, compared to 1763078400 on 3393844. Therefore, it implies a Short% of Shares Outstanding of 2835683 and a Short% of Float of 6.69.
Earnings Estimates
The stock of Axsome Therapeutics Inc (AXSM) is currently being evaluated by 15.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$0.67, with high estimates of -$0.43 and low estimates of -$1.1.
Analysts are recommending an EPS of between -$3.52 and -$4.28 for the fiscal current year, implying an average EPS of -$3.89. EPS for the following year is $0.39, with 14.0 analysts recommending between $3.72 and -$3.63.
Revenue Estimates
18 analysts predict $187.02M in revenue. The current quarter. It ranges from a high estimate of $195.2M to a low estimate of $180.75M. As of . The current estimate, Axsome Therapeutics Inc’s year-ago sales were $118.77MFor the next quarter, 18 analysts are estimating revenue of $189.85M. There is a high estimate of $203.7M for the next quarter, whereas the lowest estimate is $177.68M.
A total of 20 analysts have provided revenue estimates for AXSM’s current fiscal year. The highest revenue estimate was $637.7M, while the lowest revenue estimate was $623.25M, resulting in an average revenue estimate of $629.53M. In the same quarter a year ago, actual revenue was $385.69MBased on 20 analysts’ estimates, the company’s revenue will be $988.78M in the next fiscal year. The high estimate is $1.11B and the low estimate is $840.8M.
